Apollon Formularies (AQSE:APOL) Additional Paid-In Capital : £54.67 Mil(As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Additional Paid-In Capital?

Apollon Formularies's quarterly additional paid-in capital increased from Dec. 2021 (£54.05 Mil) to Jun. 2022 (£54.34 Mil) and increased from Jun. 2022 (£54.34 Mil) to Jun. 2023 (£54.67 Mil).

Apollon Formularies's annual additional paid-in capital declined from Dec. 2019 (£11.71 Mil) to Dec. 2020 (£3.91 Mil) but then increased from Dec. 2020 (£3.91 Mil) to Dec. 2021 (£54.05 Mil).

Apollon Formularies Additional Paid-In Capital Historical Data

The historical data trend for Apollon Formularies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Additional Paid-In Capital Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Additional Paid-In Capital

Get a 7-Day Free Trial

8.65

8.63

11.71

3.91

54.05

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial											3.91	54.05	54.05	54.34	54.67

Apollon Formularies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Apollon Formularies Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.